Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BMRA

BMRA - Biomerica Inc Stock Price, Fair Value and News

$2.42-0.02 (-0.82%)
Market Closed

22/100

BMRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

BMRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.06

Target 3M

$2.36

Target 6M

$2.18

BMRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMRA Price Action

Last 7 days

-2.0%

Last 30 days

-9.0%

Last 90 days

-12.3%

Trailing 12 Months

-55.5%

BMRA RSI Chart

BMRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMRA Valuation

Market Cap

7.3M

Price/Earnings (Trailing)

-1.82

Price/Sales (Trailing)

1.64

EV/EBITDA

-1.21

Price/Free Cashflow

-2.46

BMRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.06

Target 3M

$2.36

Target 6M

$2.18

BMRA Fundamentals

BMRA Revenue

Revenue (TTM)

4.5M

Rev. Growth (Yr)

-26.04%

Rev. Growth (Qtr)

-12.32%

BMRA Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

-38.95%

Earnings Growth (Qtr)

-66.1K%

BMRA Profitability

Operating Margin

5.57%

EBT Margin

-90.10%

Return on Equity

-90.76%

Return on Assets

-66.71%

Free Cashflow Yield

-40.57%

BMRA Investor Care

Shares Dilution (1Y)

31.76%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20255.7M5.3M4.9M4.5M
20245.4M5.4M5.5M5.6M
20239.5M5.3M5.4M5.5M
202214.6M18.9M19.2M16.1M
20218.9M7.2M7.3M10.6M
20205.1M6.7M6.6M6.4M
20195.2M5.2M5.1M5.2M
20185.9M5.6M5.4M5.3M
20175.7M5.8M5.8M6.0M
20165.3M5.1M5.3M5.5M
20155.1M5.0M5.2M5.2M
20144.9M5.1M5.1M5.3M
20136.5M6.5M5.8M4.8M
20125.8M6.1M6.4M6.6M
201104.9M5.1M5.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Biomerica Inc

BMRA
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
 CEO
 WEBSITEbiomerica.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES62

Biomerica Inc Frequently Asked Questions

BMRA is the stock ticker symbol of Biomerica Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Biomerica Inc is 7.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BMRA's fair value in chart for subscribers.

The fair value guage provides a quick view whether BMRA is over valued or under valued. Whether Biomerica Inc is cheap or expensive depends on the assumptions which impact Biomerica Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRA.

As of Wed Jan 28 2026, BMRA's PE ratio (Price to Earnings) is -1.82 and Price to Sales (PS) ratio is 1.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Biomerica Inc has provided -0.125 (multiply by 100 for percentage) rate of return.